ArticleDrug, healthcare and patient safety2026
Metoclopramide and Risk of Pheochromocytoma Crisis: A Causality Assessment Using Literature and VigiBase Data.
Article in Drug, healthcare and patient safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The association between metoclopramide and pheochromocytoma crisis has been documented in literature. However, evidence has primarily relied on case reports and small-scale experimental studies rather than rigorous causal assessments. Therefore, this study aimed to assess the causal relationship between metoclopramide use and the occurrence of pheochromocytoma crisis by analyzing data from the literature and World Health Organization (WHO) global pharmacovigilance database. Methods: This study was a descriptive analysis and causality assessment of metoclopramide and pheochromocytoma crisis. Data were retrieved from published literature and the WHO global pharmacovigilance database (VigiBase) on February 13, 2025. In addition to the causality results extracted from VigiBase, causality assessment at the individual level for published case reports was conducted using the Naranjo Adverse Drug Reaction Probability Scale. Causality assessment at the population level was conducted using the Austin Bradford-Hill causality assessment framework. Results: A total of 62 de-duplicate cases were found in VigiBase and the literature. Almost all cases were classified as serious with 12 fatalities. In many instances, the drug-induced crisis served as the first clinical indication of an undiagnosed (occult) tumor. A causality assessment using the Naranjo algorithm conducted by the current authors classified the 18 published cases as "probable" (13) and "possible" (5). In VigiBase, causality assessment at the individual level was reported for 10 cases, with possible (6), probable (2), and reasonable possibilities (2). The results of the causality assessment at the population level using Hill's criteria revealed compelling evidence across all nine criteria. Conclusion: A reasonable causal relationship exists between metoclopramide and pheochromocytoma crisis, supporting its contraindication in patients with known or suspected pheochromocytoma.Clinicians should monitor patients, consider underlying pheochromocytoma, and be aware of this risk. Further international case-control studies are recommended to confirm this causal association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.